Genetic variation associated with bortezomib-induced peripheral neuropathy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2011-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/FPC.0b013e3283436b45PMID 21228734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action.

  2010cited by this paper
• Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.

  2010cited by this paper
• Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

  2010cited by this paper
• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

  2010cited by this paper
• Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.

  2009cited by this paper
• Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

  2009cited by this paper
• A pilot genome-wide association study of early-onset breast cancer

  2009cited by this paper
• Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway.

  2009cited by this paper
• Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

  2009cited by this paper
• Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

  2009cited by this paper
• CpG methylation in exon 1 of transcription factor 4 increases with age in normal gastric mucosa and is associated with gene silencing in intestinal-type gastric cancers

  2008cited by this paper
• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

  2008cited by this paper
• Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.

  2008cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature

  2007cited by this paper
• Interaction of the DYNLT (TCTEX1/RP3) Light Chains and the Intermediate Chains Reveals Novel Intersubunit Regulation during Assembly of the Dynein Complex*

  2007cited by this paper
• Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

  2007cited by this paper
• Role of the cysteine protease cathepsin S in neuropathic hyperalgesia

  2007cited by this paper
• Use of Immunoglobulin Infusions in the Management of Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma.

  2006cited by this paper
• DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1.

  2006cited by this paper
• Molecular profiling of murine sensory neurons in the nodose and dorsal root ganglia labeled from the peritoneal cavity.

  2006cited by this paper
• Comprehensive association testing of common mitochondrial DNA variation in metabolic disease.

  2006cited by this paper
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

  2006cited by this paper
• Towards a proteome-scale map of the human protein–protein interaction network

  2005cited by this paper
• Nudel functions in membrane traffic mainly through association with Lis1 and cytoplasmic dynein

  2004cited by this paper
• Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders.

  2004cited by this paper
• Signaling to NF-kappaB.

  2004cited by this paper
• BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping.

  2002cited by this paper
• Connexin29 Is Uniquely Distributed within Myelinating Glial Cells of the Central and Peripheral Nervous Systems

  2002cited by this paper
• Cytoplasmic Changes in Satellite Cells of Spinal Ganglia Induced by Cisplatin Treatment in Rats

  2000cited by this paper
• Mutation Detection in K‐ras, BRCA1, BRCA2, and p53 Using PCR/LDR and a Universal DNA Microarray

  2000cited by this paper
• Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy.

  2000cited by this paper

• Contributions of neuroimmune interactions to chemotherapy-induced peripheral neuropathy development and its prevention/therapy.

  2024cites this paper
• Genetic risk factors for bortezomib-induced neuropathic pain in an Asian population: A genome-wide association study in South Korea.

  2024cites this paper
• A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients

  2024cites this paper
• Proteomic Analysis of Rat Duodenum Reveals the Modulatory Effect of Boron Supplementation on Immune Activity

  2023cites this paper
• Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction

  2023cites this paper
• Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions

  2022cites this paper
• Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity.

  2022cites this paper
• Predisposing Factors for the Development of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

  2021cites this paper
• Drug-Induced Peripheral Neuropathy: Diagnosis and Management.

  2021cites this paper
• Role of innate immunity in chemotherapy-induced peripheral neuropathy.

  2021cites this paper
• Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease

  2020cites this paper
• PGPM_A_270069 463..484

  2020cites this paper
• Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease

  2020cites this paper
• Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease

  2020cites this paper
• A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients

  2020cites this paper
• Peripheral neuropathy in hematologic malignancies - Past, present and future.

  2020cites this paper
• Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment

  2019cites this paper
• Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.

  2019cites this paper
• Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview

  2019cites this paper
• Six Sessions of Once-Weekly Bortezomib Treatment Induced Ileus in a Patient with Multiple Myeloma

  2019cites this paper
• CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens

  2018cites this paper
• Gene expression based risk classification in multiple myeloma

  2018cites this paper
• Model-based clustering for identifying disease-associated SNPs in case-control genome-wide association studies

  2018cites this paper
• Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics

  2017cites this paper
• Chemotherapieinduzierte periphere Neuropathie

  2017cites this paper
• Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma

  2017cites this paper
• European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

  2017cites this paper
• Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

  2017cites this paper
• Chemotherapie-induzierte periphere Neuropathie und neuropathischer Schmerz

  2017cites this paper
• Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci

  2017cites this paper
• Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

  2017cites this paper
• Simvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 Protein

  2016cites this paper
• A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients Running title : GWAS in multiple myeloma pharmacogenomics

  2016cites this paper
• Polymorphisms of the TCF4 gene are associated with the risk of schizophrenia in the Han Chinese

  2016cites this paper
• Pharmacogenomics in pain treatment

  2016cites this paper
• A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

  2016cites this paper
• A Genome-Wide Association Study Identi fi es a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

  2016cites this paper
• Managing treatment-related peripheral neuropathy in patients with multiple myeloma

  2016cites this paper
• An Overview of Bortezomib-Induced Neurotoxicity

  2015cites this paper
• Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

  2015cites this paper
• Informative gene network for chemotherapy-induced peripheral neuropathy

  2015cites this paper
• Mechanisms of Astrocyte Contribution to Bortezomib-Induced Peripheral Neuropathy

  2014cites this paper
• Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy

  2014cites this paper
• Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.

  2014cites this paper
• Number (%) of Number of patients in patients the overall treated with population sc VTD/VCD

  2014cites this paper
• Resistance to Proteasome Inhibitors in Cancer

  2014cites this paper
• Analysis of Incidence and Risk Factors for Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma

  2014cites this paper
• Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy.

  2014cites this paper
• Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma

  2014cites this paper
• Bortezomib in multiple myeloma: systematic review and clinical considerations.

  2014cites this paper
• Multiple Myeloma and Evolution of Novel Biomarkers and Therapies

  2014cites this paper
• Bortezomib-induced peripheral neurotoxicity: an update

  2014cites this paper
• Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

  2014cites this paper
• Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

  2014cites this paper
• Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy

  2014cites this paper
• Bortezomib‐ and thalidomide‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study

  2014cites this paper
• Neurotoxicity induced by antineoplastic proteasome inhibitors.

  2014cites this paper
• Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management

  2013cites this paper
• Antibody against tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model.

  2013cites this paper
• Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy

  2013cites this paper
• 2 Predictors of Chemotherapy-Induced Peripheral Neuropathy

  2012cites this paper
• Management of treatment-emergent peripheral neuropathy in multiple myeloma

  2012cites this paper
• Neuropatia induïda per Bortezomib. Caracterització i factors de risc en un model experimental

  2012cites this paper
• European perspective on multiple myeloma treatment strategies: update following recent congresses.

  2012cites this paper
• Predictors of Chemotherapy-Induced Peripheral Neuropathy

  2012cites this paper
• Genetic variations in multiple myeloma II: association with effect of treatment

  2012cites this paper
• The future of treatment for patients with relapsed/refractory multiple myeloma: The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma

  2011cites this paper
• Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

  2011influential citation
• An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.

  2011cites this paper
• The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

  2011cites this paper
• Polymorphisms Contribution to the Determination of Significant Risk of Specific Toxicities in Multiple Myeloma

  2011cites this paper
• Reducing neurotoxicity in the management of multiple myeloma

  2011cites this paper
• Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.

  2011cites this paper
• Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

  2011influential citation